Pfizer, BioNTech complete FDA submission for new COVID-19 booster


Pfizer Inc. PFE, -0.18% and BioNTech SE BNTX, +0.56% said Monday that they formally completed an application asking the Food and Drug Administration to authorize their experimental bivalent COVID-19 booster in those who are 12 years old or older. The new shot equally targets the original strain of the virus and the BA.4 and BA.5 strains. BA.5 is the most dominant strain of SARS-CoV-2 in the U.S. right now. Moderna Inc. MRNA, -1.69% is also developing a bivalent COVID-19 booster. So far this year, Pfizer’s stock is down 16.9%, while shares of BioNTech have tumbled 42.3%. The S&P 500 SPX, -1.61% has declined 11.3%.

This article was originally published by Read the original article here.

Previous article: Baby-formula shortage is finally easing, although some states are still seeing high out-of-stock rates
Next articleAMC’s ‘APEs’ open for trading on the NYSE


Please enter your comment!
Please enter your name here